Related references
Note: Only part of the references are listed.Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata
M. Broadstock et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease
Matthew J. Betts et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors
Fabio Blandini et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Perampanel, an AMPA antagonist, found to have no benefit in reducing off time in Parkinson's disease
Andrew Lees et al.
MOVEMENT DISORDERS (2012)
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias
Fabrizio Gardoni et al.
NEUROBIOLOGY OF AGING (2012)
Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?
Filippo Caraci et al.
NEUROCHEMISTRY INTERNATIONAL (2012)
Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model
Ming-Hong Hsieh et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
Veronique Sgambato-Faure et al.
PROGRESS IN NEUROBIOLOGY (2012)
The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with L-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease
Carrie K. Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys
Gunasingh J. Masilamoni et al.
BRAIN (2011)
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
Imtiaz Ahmed et al.
BRAIN (2011)
Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions
Li Chen et al.
BRAIN RESEARCH BULLETIN (2011)
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Susan Duty et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
Kristin B. Dupre et al.
EXPERIMENTAL NEUROLOGY (2011)
Discovery, Synthesis, and Structure-Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4) with Oral Efficacy in an Antiparkinsonian Animal Model
Carrie K. Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Management of punding in Parkinson's disease: an open-label prospective study
A. Fasano et al.
JOURNAL OF NEUROLOGY (2011)
The Metabotropic Glutamate Receptor 7 Allosteric Modulator AMN082: A Monoaminergic Agent in Disguise?
Stacey J. Sukoff Rizzo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective
Filippo Caraci et al.
MOLECULAR PHARMACOLOGY (2011)
Etiology and Pathogenesis of Parkinson's Disease
Anthony H. Schapira et al.
MOVEMENT DISORDERS (2011)
AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials
Daniela Berg et al.
MOVEMENT DISORDERS (2011)
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications
Bazoumana Ouattara et al.
NEUROBIOLOGY OF AGING (2011)
GluR1 Phosphorylation and Persistent Expression of Levodopa-induced Motor Response Alterations in the Hemi-Parkinsonian Rat
Maowen Ba et al.
NEUROCHEMICAL RESEARCH (2011)
Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia
Bernardino Ossola et al.
NEUROPHARMACOLOGY (2011)
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys
Laurent Gregoire et al.
PARKINSONISM & RELATED DISORDERS (2011)
Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia
M.M. Iravani et al.
PARKINSONISM & RELATED DISORDERS (2011)
Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia
Joanna M. Wierońska et al.
PSYCHOPHARMACOLOGY (2011)
The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2
Pier L. D'Alessandro et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease
G. Ambrosi et al.
BRAIN RESEARCH BULLETIN (2010)
Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease
Susan Duty
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease
P. J. Austin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease
Christopher Kobylecki et al.
JOURNAL OF NEUROCHEMISTRY (2010)
The clinical spectrum of levodopa-induced motor complications
E. Hametner et al.
JOURNAL OF NEUROLOGY (2010)
Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease
B. Greco et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
Tom H. Johnston et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Paolo Calabresi et al.
LANCET NEUROLOGY (2010)
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Murat Emre et al.
LANCET NEUROLOGY (2010)
NMDA Antagonist Memantine Improves Levodopa-Induced Dyskinesias and On-Off Phenomena in Parkinson's Disease
Sara Varanese et al.
MOVEMENT DISORDERS (2010)
Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
Elisabeth Wolf et al.
MOVEMENT DISORDERS (2010)
Safety and Efficacy of Perampanel in Advanced Parkinson's Disease: A Randomized, Placebo-Controlled Study
Karla Eggert et al.
MOVEMENT DISORDERS (2010)
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
Daniella Rylander et al.
NEUROBIOLOGY OF DISEASE (2010)
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys
Nicolas Morin et al.
NEUROPHARMACOLOGY (2010)
Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems
Joanna M. Wieronska et al.
NEUROPHARMACOLOGY (2010)
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism
Melanie A. Paquette et al.
NEUROPHARMACOLOGY (2010)
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides
Mohamed Khalil Tamim et al.
NEUROPHARMACOLOGY (2010)
GROUP II METABOTROPIC GLUTAMATE RECEPTOR ACTIVATION BY AGONIST LY379268 TREATMENT INCREASES THE EXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR IN THE MOUSE BRAIN
V. Di Liberto et al.
NEUROSCIENCE (2010)
CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS
B. Ouattara et al.
NEUROSCIENCE (2010)
Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease
Yolanda D. Black et al.
NEUROSCIENCE LETTERS (2010)
Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia
Emanuela Santini et al.
PLOS ONE (2010)
Characterisation of the Expression of NMDA Receptors in Human Astrocytes
Ming-Chak Lee et al.
PLOS ONE (2010)
Glutamate receptors, neurotoxicity and neurodegeneration
Anthony Lau et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2010)
Synaptic Recruitment of AMPA Glutamate Receptor Subunits in Levodopa-Induced Dyskinesia in the MPTP-Lesioned Nonhuman Primate
Monty A. Silverdale et al.
SYNAPSE (2010)
Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDAlesion rat model
S. T. Warraich et al.
BRAIN RESEARCH BULLETIN (2009)
Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA + parafascicular lesions
L. Truong et al.
BRAIN RESEARCH BULLETIN (2009)
Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism
Corinne Beurrier et al.
FASEB JOURNAL (2009)
Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
Carol Addy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment
Dario Cuomo et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients
Pershia Samadi et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
Daniella Rylander et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
K. Ray Chaudhuri et al.
LANCET NEUROLOGY (2009)
Metabotropic Glutamate Receptors 5 Blockade Reverses Spatial Memory Deficits in a Mouse Model of Parkinson's Disease
Elvira De Leonibus et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Novel Neuroprotective Mechanisms of Memantine: Increase in Neurotrophic Factor Release from Astroglia and Anti-Inflammation by Preventing Microglial Activation
Hung-Ming Wu et al.
NEUROPSYCHOPHARMACOLOGY (2009)
METABOTROPIC GLUTAMATE mGluR5 RECEPTOR BLOCKADE OPPOSES ABNORMAL INVOLUNTARY MOVEMENTS AND THE INCREASES IN GLUTAMIC ACID DECARBOXYLASE mRNA LEVELS INDUCED BY I-DOPA IN STRIATAL NEURONS OF 6-HYDROXYDOPAMINE-LESIONED RATS
N. Yamamoto et al.
NEUROSCIENCE (2009)
Rotenone reduces Mg2+-dependent block of NMDA currents in substantia nigra dopamine neurons
Yan-Na Wu et al.
NEUROTOXICOLOGY (2009)
Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons
Giuseppe Battaglia et al.
PLOS ONE (2009)
Effects of glutamate and α2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats
Mesbah Alam et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2009)
Review: Improving symptom control in early Parkinson’s disease
Stuart H. Isaacson et al.
Therapeutic Advances in Neurological Disorders (2009)
Combined 5-HTIA and 5-HTIB receptor agonists for the treatment of L-DOPA-induced dyskinesia
Ana Munoz et al.
BRAIN (2008)
NEUROPROTECTIVE EFFECTS OF A SELECTIVE N-METHYL-D-ASPARTATE NR2B RECEPTOR ANTAGONIST IN THE 6-HYDROXYDOPAMINE RAT MODEL OF PARKINSON'S DISEASE
K. R. Leaver et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2008)
Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats
Andreas Gravius et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
John G. Nutt et al.
MOVEMENT DISORDERS (2008)
Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
Jose A. Obeso et al.
MOVEMENT DISORDERS (2008)
Molecular mechanisms of L-DOPA-induced dyskinesia
Peter Jenner
NATURE REVIEWS NEUROSCIENCE (2008)
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys
Pershia Samadi et al.
NEUROBIOLOGY OF AGING (2008)
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
Giovanna Levandis et al.
NEUROBIOLOGY OF DISEASE (2008)
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats
Sebastien Lopez et al.
NEUROPHARMACOLOGY (2008)
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias
Pershia Sarnadi et al.
NEUROPHARMACOLOGY (2008)
Pruning and loss of excitatory synapses by the parkin ubiquitin ligase
Thomas D. Helton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat
Kristin B. Dupre et al.
PSYCHOPHARMACOLOGY (2008)
Parkinson's disease and pesticides: a toxicological perspective
Jaime M. Hatcher et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage
Hossein Aleyasin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection
Corrado Corti et al.
JOURNAL OF NEUROSCIENCE (2007)
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia
Emanuela Santini et al.
JOURNAL OF NEUROSCIENCE (2007)
Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease
Sebastien Lopez et al.
JOURNAL OF NEUROSCIENCE (2007)
Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease
Alireza Kashani et al.
NEUROBIOLOGY OF AGING (2007)
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease
Flora Mela et al.
JOURNAL OF NEUROCHEMISTRY (2007)
The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats
J. Konieczny et al.
NEUROSCIENCE (2007)
The pathogenesis of cell death in Parkinson's disease - 2007
C. Warren Olanow
MOVEMENT DISORDERS (2007)
Changes in suhcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and L-dopa-treated rats
Maowen Ba et al.
NEUROCHEMICAL RESEARCH (2006)
Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia
M. Angela Cenci et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Association between amantadine and the onset of dementia in Parkinson's disease
Rivka Inzelberg et al.
MOVEMENT DISORDERS (2006)
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Giuseppe Battaglia et al.
JOURNAL OF NEUROSCIENCE (2006)
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease
A Dekundy et al.
BRAIN RESEARCH BULLETIN (2006)
Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease
MT Armentero et al.
NEUROBIOLOGY OF DISEASE (2006)
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia
F Gardoni et al.
JOURNAL OF NEUROSCIENCE (2006)
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin
M Morissette et al.
MOVEMENT DISORDERS (2006)
Phosphorylation of AMPA receptors
JQ Wang et al.
MOLECULAR NEUROBIOLOGY (2005)
Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease
AC Vernon et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
Metabotropic glutamate receptors in the basal ganglia motor circuit
PJ Conn et al.
NATURE REVIEWS NEUROSCIENCE (2005)
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets
MJ Hurley et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease
MA Silverdale et al.
MOVEMENT DISORDERS (2005)
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
PJ Hallett et al.
NEUROPHARMACOLOGY (2005)
Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP
JA Aguirre et al.
BRAIN RESEARCH (2005)
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease
PA Löschmann et al.
EXPERIMENTAL NEUROLOGY (2004)
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease
MJ O'Neill et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
G Battaglia et al.
JOURNAL OF NEUROSCIENCE (2004)
Causes of Parkinson's disease:: genetics of DJ-1
PM Abou-Sleiman et al.
CELL AND TISSUE RESEARCH (2004)
Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression
PV Massey et al.
JOURNAL OF NEUROSCIENCE (2004)
NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats
JE Kelsey et al.
PSYCHOPHARMACOLOGY (2004)
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats
RH Wessell et al.
NEUROPHARMACOLOGY (2004)
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease
JE Nash et al.
EXPERIMENTAL NEUROLOGY (2004)
Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat
N MacInnes et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease
F Calon et al.
NEUROBIOLOGY OF DISEASE (2003)
Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment
MJ Marino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture
K Shimizu et al.
NEUROSCIENCE RESEARCH (2003)
Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
G Battaglia et al.
NEUROPHARMACOLOGY (2003)
LY503430, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease
TK Murray et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Apoptosis in Parkinson's disease: Signals for neuronal degradation
WG Tatton et al.
ANNALS OF NEUROLOGY (2003)
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease
TK Murray et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2002)
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment
F Calon et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2002)
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats
C Marin et al.
SYNAPSE (2001)
Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats
K Ossowska et al.
NEUROPHARMACOLOGY (2001)
Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction
ER Matarredona et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Metabolic effects of nigrostriatal denervation in basal ganglia
EC Hirsch et al.
TRENDS IN NEUROSCIENCES (2000)
Functional changes of the basal ganglia circuitry in Parkinson's disease
F Blandini et al.
PROGRESS IN NEUROBIOLOGY (2000)
Association between early-onset Parkinson's disease and mutations in the parkin gene
CB Lücking et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
S Konitsiotis et al.
NEUROLOGY (2000)
Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors
K Steece-Collier et al.
EXPERIMENTAL NEUROLOGY (2000)
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat
L Dawson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients
MA Kuiper et al.
JOURNAL OF NEURAL TRANSMISSION (2000)
Synaptic localization of ionotropic glutamate receptors in the rat substantia nigra
BT Chatha et al.
NEUROSCIENCE (2000)
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease
JE Nash et al.
EXPERIMENTAL NEUROLOGY (2000)
Share Paper
